Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112469 | 0.91 | — | — | |
| Water SCHEMBL7929821 | 0.88 | LMNA (0.37) | LMNAALDH1A1CA2 | |
| Water SCHEMBL5127632 | 0.88 | LMNA (0.37) | LMNAALDH1A1CA2 | |
| Water SCHEMBL6763348 | 0.88 | LMNA (0.37) | LMNAALDH1A1CA2 | |
| Trifluoroacetic Acid SCHEMBL28287909 | 0.82 | LMNA (0.62) | LMNAALDH1A1TP53TSHRCA2 | |
| Trifluoroacetic Acid SCHEMBL18167021 | 0.82 | ALDH1A1 (0.41) | LMNAALDH1A1TP53TSHRCA2 | |
| Trifluoroacetic Acid SCHEMBL269102 | 0.82 | ALDH1A1 (0.41) | LMNAALDH1A1TP53TSHRCA2 | |
| Trifluoroacetic Acid SCHEMBL28012644 | 0.79 | ALDH1A1 (0.39) | LMNAALDH1A1TP53TSHRCA2 | |
| Trifluoroacetic Acid SCHEMBL9003919 | 0.77 | ALDH1A1 (0.37) | LMNAALDH1A1TP53TSHRCA2 | |
| Trifluoroacetic Acid SCHEMBL3055318 | 0.77 | ALDH1A1 (0.38) | LMNAALDH1A1TP53TSHRCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534680-B1 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | PHARMACO INVESTMENTS INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20110200528-A1 | CYCLIZED NGR PEPTIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF THEIR USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA | 2011-08-18 | — | — | US | disclosed |
| EP-1833978-B1 | TRIPEPTIDE AND TETRAPEPTIDE THIOETHERS | TELIK INC (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1833842-B1 | TRIPEPTIDE AND TETRAPEPTIDE SULFONES | TELIK INC (US) | 2008-10-08 | — | — | EP | disclosed |
| US-7192918-B2 | Tripeptide and tetrapeptide sulfones | TELIK, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7129215-B2 | Tripeptide and tetrapeptide thioethers | TELIK, INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060160749-A1 | TRIPEPTIDE AND TETRAPEPTIDE THIOETHERS | TELIK, INC. | 2006-07-20 | — | — | US | disclosed |
| US-20060148719-A1 | Tripeptide and tetrapeptide sulfones | TELIK, INC. | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160749-A1 | TRIPEPTIDE AND TETRAPEPTIDE THIOETHERS | MCL1, THPO, MYADM | LMNA 4748/4885ALDH1A1 3287/4885TP53 113/4885 |
| US-20060148719-A1 | Tripeptide and tetrapeptide sulfones | MCL1, MYD88, MYADM | LMNA 4319/4885ALDH1A1 3662/4885TP53 75/4885 |
| US-20110200528-A1 | CYCLIZED NGR PEPTIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF THEIR USE | NGLY1, GRPR, GIPR | LMNA 1788/4885ALDH1A1 4878/4885TP53 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.